
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. has demonstrated strong sales momentum with Baqsimi, reflecting a nearly 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, which positions the company for favorable growth in 2025 and 2026. The company anticipates a return to double-digit growth by 2026, supported by expected high-single digit unit growth in 2025 and strong performance from Primatene Mist during the upcoming fall and winter seasons. Additionally, favorable market conditions indicate that Amphastar's top-line growth could align more closely with industry peers, thereby enhancing its overall financial outlook.
Bears say
Amphastar Pharmaceuticals Inc. faces a negative outlook primarily due to significant revisions in sales expectations for key products, particularly iron sucrose and glucagon, which are projected to experience substantial decline amid increasing competition. Sales estimates for iron sucrose have been drastically reduced from an anticipated $60 million annually to around $20 million, while glucagon revenues are expected to fall below $70 million starting in 2026, impacted by the entry of multiple competitors into the market. Additionally, the firm's forecast for top-line growth has been downgraded from double-digit growth to a more modest range of high-single to low-double digits, reflecting ongoing pressures from their product pipeline and market dynamics.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares